Alteogen Inc.
KOSDAQ-listed biotech behind the Hybrozyme IV-to-SC platform and the Eyluxvi Eylea biosimilar.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2008 and listed on KOSDAQ in 2014, Alteogen is a biotech company specializing in biobetters and biosimilars. It out-licenses platform technologies to global pharmaceutical companies including MSD, AstraZeneca, GSK, Daiichi Sankyo, and Sandoz, including Hybrozyme™ (hyaluronidase technology converting IV to SC formulations), NexP™ (long-acting biologics fusion technology), and NexMab™ (antibody-drug conjugate technology). Its core asset ALT-B4 (berahyaluronidase alfa) was commercialized as a standalone injection (Tergase Inj.) in 2024; its Herceptin biosimilar was out-licensed to Qilu Pharmaceutical of China and commercialized there in 2024, generating royalty income; and its Eylea biosimilar Eyluxvi® completed global Phase 3 trials in 2024 and received European marketing authorization in September 2025.
Products & technology
- ALT-B4 (berahyaluronidase alfa)Hyaluronidase enabling IV-to-SC formulation conversion
- Tergase Inj. (ALT-B4 standalone injection)Standalone hyaluronidase injection for pain and swelling relief
- Herceptin biosimilarAntibody biosimilar for breast cancer treatment
- Eyluxvi (Eylea biosimilar)Antibody biosimilar for ophthalmic disease treatment
Regulatory approvals
data.go.kr2 Korean MFDS drug approvals · 2024–2026
- MFDS drugEYZANFY Injection(Aflibercept)2026-05-14Drug · Prescription · Approval202601428
- MFDS drugTergase Injection(Berahyaluronidase alfa(Recombinant hyaluronidase))2024-07-05Drug · Prescription · Approval202401660
Clinical trials
data.go.kr4 MFDS clinical trial authorisations · 2017–2021 (Phase 1 3 · Phase 1/2a 1)
- Phase 1ALT-BB42021-09-15
4 trial sites
- Phase 1ALT-L92019-05-21
4 trial sites
- Phase 1/2aALT-P12017-07-11
3 trial sites
- Phase 1ALT-P72017-06-16
2 trial sites
R&D and key agreements
Source: DART corporate disclosureNexP™ 융합기술 · 플랫폼 기술 · Long-acting biologics fusion technology
NexMab™ (ADC 기술) · 플랫폼 기술 · Next-generation antibody-drug conjugate technology
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition